Management of multiple sclerosis

American Journal of Managed Care

Volumn 19, Issue 16 SUPPL., 2013, Pages

  Ross, Amy Perrin ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BETA INTERFERON; CD52 ANTIGEN; CORTICOSTEROID; FINGOLIMOD; LAQUINIMOD; METHYLPREDNISOLONE; NATALIZUMAB; OCRELIZUMAB;

CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; NEUROLOGIST; OPTIC NEURITIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PREFERENCE; PHARMACEUTICAL CARE; PHARMACOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF-DIRECTED LEARNING; SLEEP DEPRIVATION; SOCIAL ISOLATION; TREATMENT REFUSAL; DISEASE MANAGEMENT; FEMALE; INTERDISCIPLINARY COMMUNICATION; MALE; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; PSYCHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MONITORING, PHYSIOLOGIC; MULTIPLE SCLEROSIS; PATIENT EDUCATION AS TOPIC; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84903835272     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. National Multiple Sclerosis Society. Fact sheet: multiple sclerosis. http://www.nationalmssociety.org/chapters/mnm/mediacenter/ factsheetmultiplesclerosis/index.aspx. Accessed August 13, 2013.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313): 1221-1231. (Pubitemid 34304266)
3. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616. (Pubitemid 43278223)
4. Pittock SJ, Mayr WT, McClelland RL, et al. Quality of life is favorable for most patients with multiple sclerosis: a populationbased cohort study. Arch Neurol. 2004;61(5):679-686. (Pubitemid 38637684)
5. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702. (Pubitemid 43964625)
6. Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One. 2013;8(1):e54756.
7. McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A. Drug class review on disease-modifying drugs for multiple sclerosis. Portland, OR: Oregon Health & Science University; July 2007.
8. Ross AP, Hackbarth N, Rohl C, Whitmyre K. Effective multiple sclerosis management through improved patient assessment. J Neurosci Nurs. 2008;40(3):150-157.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911.
10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
11. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci. 2007;256(suppl 1):S14-S18. (Pubitemid 46560637)
12. Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2012;12:CD006921.
13. Frohman EM, Eagar T, Monson N, Stuve O, Karandikar N. Immunologic mechanisms of multiple sclerosis. Neuroimaging Clin N Am. 2008;18(4):577-588.
14. Thrower BW. Relapse management in multiple sclerosis. Neurologist. 2009;15(1):1-5.
15. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652-659. (Pubitemid 44273613)
16. Beck RW, Cleary PA, Trobe JD, et al The Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993;329(24):1764-1769. (Pubitemid 23355549)
17. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247(6):435-442. (Pubitemid 30433557)
18. Vedula SS, Brodney-Folse S, Gal RL, et al. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2007; 1:CD001430.
19. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997;349(9056):902-906. (Pubitemid 27139818)
20. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56(11):1219-1220. (Pubitemid 23323664)
21. Craig J, Young CA, Ennis M, Baker G, Boggild M. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry. 2003; 74(9):1225-1230.
22. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008; 10(9):225.
23. Smrtka J, Caon C, Saunders C, Becker BL, Baxter N. Enhancing adherence through education. J Neurosci Nurs. 2010;42(5 suppl):S19-S29.
24. Ross AP. Tolerability, adherence, and patient outcomes. Neurology. 2008;71(24 suppl 3):S21-S23.
25. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. (Pubitemid 351160875)
26. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54(5):531-533. (Pubitemid 27204238)
27. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007;259(1-2):104-108. (Pubitemid 47031209)
28. Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol. 2011;24(3):230-237.
29. Coyle PK. Switching therapies in multiple sclerosis. CNS Drugs. 2013;27(4):239-247.
30. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13(1):90-98.
31. Agashivala N, Kim E. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Clin Ther. 2012;34(7):1583-1590.
32. DeAngelis T, Lublin F. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J Med. 2008;75(2):157-167.
33. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(pt 8):2232-2247.
34. Teva Pharmaceutical Industries Ltd. Results of phase III BRAVO trial reinforce unique profile of laquinimod for multiple sclerosis treatment. http://hugin.info/1002/R/1535269/468107.pdf. Published August 1, 2011. Accessed August 15, 2013.
35. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
36. Krieger S. Multiple sclerosis therapeutic pipeline: opportunities and challenges. Mt Sinai J Med. 2011;78(2):192-206.
37. Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol. 2009;16(4): e70-e71.
38. Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology. 2010;74(suppl 1):S31-S40.
39. Coles AJ, Compston DA, Selmaj KW, et al; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.